Reata Pharmaceuticals Inc. (NASDAQ:RETA) finished Wednesday with a subtraction of -$0.05 to close at $167.11, a downside of -0.03 percent. An average of 1,202,060 shares of common stock have been traded in the last five days. There was a gain of $0.60 in the past week, and it reached a new high 43 times over the past 12 months. The last 20 days have seen an average of 1,471,275 shares traded, while the 50-day average volume stands at 1,017,026.
RETA stock has increased by 52.86% in the last month. The company shares reached their 1-month lowest point of $103.22 on 07/10/23. With the stock rallying to its 52-week high on 08/09/23, shares of the company touched a low of $18.47 and a high of $167.60 in 52 weeks. It has reached a new high 31 times so far this year and achieved 339.88% or $129.12 in price. In spite of this, the price is down -0.29% from the 52-week high.
Insider Transactions
RETA stock investors should be aware that Reata Pharmaceuticals Inc. (RETA) stock had its last reported insider trading activity 13 days ago on Jul 28. In this transaction, the insider spent $12,346,298. Chief Commercial Officer, Bir Dawn Carter, disposed of 40,000 shares at a price of $164.54 on Jul 28. The insider now owns more than $6,581,428 worth of shares. Prior to that, Director Ruff Shamim went on to Sale 8,235 shares at $164.53 each on Jul 28. An amount of $1,354,887 was transacted.
Valuation Metrics
Reata Pharmaceuticals Inc. (RETA) stock’s beta is 1.42. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4236.80.
Financial Health
The quick ratio of Reata Pharmaceuticals Inc. for the three months ended June 29 was 6.10, and the current ratio was 6.10, indicating that the company is able to meet its debt obligations. Reata Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -12495.67%. Its gross profit as reported stood at $280.25 million compared to revenue of $2.22 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Reata Pharmaceuticals Inc.’s return on assets was -64.90%.
Earnings Surprise
For the three-month period that ended June 29, Reata Pharmaceuticals Inc. had $281.37 million in cash and short-term investments compared to $73.13 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $193.0 million in the quarter, while revenues of -$116.12 million were grew 138.11%. The analyst consensus anticipated Reata Pharmaceuticals Inc.’s latest quarter earnings to come in at -$2.88 per share, but it turned out to be -$2.26, a 21.50% surprise. For the quarter, EBITDA amounted to -$94.54 million. At the end of the quarter ending June 29, Reata Pharmaceuticals Inc.’s stock balance sheet showed total liabilities of 415.3 million. Shareholders own equity worth $38.15 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Reata Pharmaceuticals Inc. (RETA) price momentum. RSI 9-day as of the close on 09 August was 87.14%, suggesting the stock is Overbought, with historical volatility in this time frame at 212.02%.
As of today, RETA’s price is $166.85 +0.36% or $0.60 from its 5-day moving average. RETA is currently trading +53.26% higher than its 20-day SMA and +86.01% higher than its 100-day SMA. However, the stock’s current price level is +81.03% above the SMA50 and +382.14% above the SMA200.
The stochastic %K and %D were 98.32% and 98.45%, respectively, and the average true range (ATR) was 5.03. With the 14-day stochastic at 97.52% and the average true range at 5.35, the RSI (14) stands at 84.02%. The stock has reached 0.27 on the 9-day MACD Oscillator while the 14-day reading was at 21.09.
Analyst Ratings
TD Cowen launched coverage on Reata Pharmaceuticals Inc. (NASDAQ: RETA) in its analyst report released on July 06, 2023. The firm assigned the stock an Outperform rating. The consensus rating for Reata Pharmaceuticals Inc. (RETA) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell RETA, while 10 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is RETA’s price target for the next 12 months?
Analysts predict a range of price targets between $172.00 and $173.00, with a median target of $172.50. Taking a look at these predictions, the average price target given by analysts for Reata Pharmaceuticals Inc. (RETA) stock is $172.45.
